These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 31537449)

  • 1. High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.
    Christensen BR; Barata PC; Ledet EM; Layton JL; Lewis BE; Sartor O
    Clin Genitourin Cancer; 2019 Dec; 17(6):476-479. PubMed ID: 31537449
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223.
    Poon DMC; Wong KCW
    Clin Genitourin Cancer; 2018 Apr; 16(2):e397-e401. PubMed ID: 29174502
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
    George DJ
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):690-694. PubMed ID: 28949940
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
    Hu YH; Guo JC; Zhang M
    Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Castration resistant prostate cancer 2015].
    Merseburger AS; Böker A; Kuczyk MA; von Klot CA
    Aktuelle Urol; 2015 Jan; 46(1):59-65. PubMed ID: 25658232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.
    Ramos JD; Mostaghel EA; Pritchard CC; Yu EY
    Clin Genitourin Cancer; 2018 Apr; 16(2):106-110. PubMed ID: 29287968
    [No Abstract]   [Full Text] [Related]  

  • 8. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):15-6. PubMed ID: 27167846
    [No Abstract]   [Full Text] [Related]  

  • 10. eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.
    Shore ND; Tutrone RF; Mariados NF; Nordquist LT; Mehlhaff BA; Steere KJ; Harrelson SS
    Clin Genitourin Cancer; 2018 Apr; 16(2):149-154. PubMed ID: 29196208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
    BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in metastatic prostate cancer therapy.
    Manickavasagar T; Gilson C; Chowdhury S; Kirby R
    Practitioner; 2015 Apr; 259(1781):21-4, 2-3. PubMed ID: 26529826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radium 223 dichloride for prostate cancer treatment.
    Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
    Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.
    Yu EY; Oh WK
    Asian J Androl; 2014; 16(3):331-3. PubMed ID: 24759585
    [No Abstract]   [Full Text] [Related]  

  • 16. Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):10-1. PubMed ID: 27167843
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate-Specific Antigen Flare Phenomenon During
    De Vincentis G; Follacchio GA; Frantellizzi V; Liberatore M; Monteleone F; Cortesi E
    Clin Genitourin Cancer; 2016 Oct; 14(5):e529-e533. PubMed ID: 27212044
    [No Abstract]   [Full Text] [Related]  

  • 18. Radium-223 international early access program: results from the Spanish subset.
    Carles J; Méndez MJ; Pinto Á; Sáez MI; Arranz JA; Maroto P; López-Criado P; Mellado B; Donas JG; Hernando S; León L; Del Alba AG; Laínez N; Esteban E; Reynés G; Pérez-Gracia JL; Germà JR; López-Brea M; Pérez-Valderrama B; Moretones C; Castellano D
    Future Oncol; 2018 Jan; 14(1):41-50. PubMed ID: 29232987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.